viral
diseas
continu
pose
greatest
challeng
modern
medicin
mani
viral
diseas
prophylact
vaccin
unlik
develop
near
futur
fortun
effect
antivir
therapi
develop
mani
virus
review
focu
antivir
therapi
herp
simplex
viru
human
immunodefici
viru
hepat
c
viru
human
papillomaviru
develop
compound
target
virus
illustr
mani
principl
drive
current
antivir
develop
like
increas
understand
viral
replic
virushost
interact
lead
rapid
develop
new
antivir
futur
virus
caus
devast
diseas
afflict
human
smallpox
thought
arisen
year
ago
kill
million
peopl
erad
similarli
poliomyel
caus
paralyt
diseas
sinc
ancient
time
fortun
effect
vaccin
develop
diseas
vaccin
led
erad
smallpox
seem
like
achiev
erad
wildtyp
poliomyel
nottoodist
futur
howev
press
viral
pathogen
today
vaccin
avail
thu
despit
fact
million
peopl
current
live
human
immunodefici
viru
hiv
infect
unaidswho
estim
prophylact
vaccin
avail
break
cycl
new
infect
similarli
vaccin
avail
prevent
hepat
c
viru
hcv
infect
estim
infect
peopl
worldwid
lead
million
death
due
cirrhosi
hepatocellular
carcinoma
vaccin
avail
prevent
infect
herp
simplex
viru
type
affect
one
five
american
fact
much
effort
expend
attempt
develop
vaccin
diseas
notabl
lack
success
might
argu
easi
viral
candid
vaccin
develop
exhaust
virus
hcv
hiv
pose
uniqu
challeng
due
rapid
antigen
variat
virus
herp
simplex
virus
potent
immun
escap
mechan
includ
establish
lifelong
latenc
thu
develop
new
vaccin
virus
like
slow
labori
process
togeth
increas
awar
emerg
viral
agent
west
nile
viru
sar
coronaviru
ebola
tortuou
path
new
vaccin
sober
prospect
fortun
anoth
path
manag
viral
infect
open
develop
specif
antivir
compound
advent
compound
allow
effect
manag
viral
diseas
herpesviru
infect
hiv
infect
aid
even
made
possibl
cure
viral
infect
hcv
purpos
articl
review
develop
import
antivir
compound
illustr
principl
process
guid
current
develop
antivir
therapi
hightlight
area
like
yield
signific
progress
futur
focu
mainli
four
virus
alphaherpesvirus
among
first
virus
success
treat
target
therapi
hiv
drug
avail
hiv
viral
infect
hcv
magnitud
clinic
impact
fact
hcv
may
amen
true
cure
human
papilloma
viru
hpv
infect
illustr
concept
immun
respons
modifi
clinic
treatment
path
develop
effect
antivir
mani
way
open
earlier
develop
antibacteri
compound
although
first
antibacteri
introduct
penicillin
clinic
use
mani
way
watersh
event
demonstr
power
therapi
specif
direct
infecti
agent
develop
effect
antibacteri
progress
rapidli
littl
progress
made
virus
fact
prevail
notion
virus
command
life
process
cell
would
suscept
kind
attack
prove
effect
bacteria
late
whitley
alford
wrote
antivir
chemotherapi
remain
major
challeng
medic
scienc
particularli
contrast
satisfactori
approach
current
avail
bacteri
infect
fortun
author
other
foresight
understand
develop
effect
antivir
go
requir
serendip
need
deep
understand
work
viral
replic
cycl
relationship
host
cell
put
comprehend
difficulti
current
approach
antivir
appropri
review
rational
complex
develop
avail
compound
yearli
numer
compound
synthes
random
basi
structur
alter
known
cellular
inhibitor
manipul
undertaken
hope
produc
effect
anticanc
agent
yet
compound
also
screen
antivir
activ
specif
antivir
chemotherapi
depend
upon
identif
inhibit
viralspecif
event
replic
event
becom
understood
approach
proven
remark
fruit
follow
exampl
attest
furthermor
approach
like
continu
effect
futur
understand
deepen
fundament
biolog
viral
infect
correspond
respons
host
develop
effect
antiherpet
compound
perhap
event
set
stage
later
effort
antivir
therapi
even
today
stand
one
great
success
stori
medic
virolog
note
larg
number
nucleosid
analog
develop
screen
antineoplast
antivir
activ
idu
trifluorothymidin
tft
came
use
topic
treatment
herp
simplex
viru
hsv
kerat
unfortun
compound
unaccept
toxic
system
use
anoth
socal
first
gener
antiherpet
vidarabin
araa
suffici
welltoler
system
therapi
found
use
herp
enceph
neonat
herp
varicella
zoster
infect
vidarabin
analog
adenin
activ
cellular
enzym
form
triphosph
form
inhibit
hsv
dna
polymeras
despit
util
vidarabin
toxic
remain
concern
triphosph
form
would
gener
cell
infect
thu
search
continu
compound
true
select
virusinfect
cell
culmin
effort
result
synthesi
guanin
guanin
deriv
posit
replac
acycl
side
chain
origin
term
acycloguanosid
compound
would
come
known
acyclovir
becom
standard
treatment
alphaherpesviru
infect
acyclovir
convert
monophosph
virusencod
thymidin
kinas
subsequ
convert
diand
triphosph
cellular
kinas
contrast
uninfect
cell
lack
viral
thymidin
kinas
prevent
gener
triphosph
form
infect
cell
triphosph
form
incorpor
viral
grow
viral
dna
chain
lead
chain
termin
acyclovir
also
directli
inhibit
viral
dna
polymeras
time
effect
cellular
polymeras
thu
acyclovir
high
degre
viral
select
remark
welltoler
drug
adopt
acyclovir
clinic
practic
rapid
demonstr
activ
anim
model
drug
use
immunosuppress
patient
cutan
system
herp
simplex
infect
remark
efficaci
lack
toxic
subsequ
becom
mainstay
therapi
genit
herp
simplex
viru
infect
shorten
time
lesion
heal
shorten
period
viral
shed
acyclovir
remain
import
compound
treatment
alphaherpesviru
infect
scientif
medic
articl
publish
regard
acyclovir
use
acyclovir
also
given
rise
relat
compound
valaciclovir
penciclovir
famciclovir
featur
slightli
differ
spectra
antivir
activ
andor
improv
pharmacodynam
unfortun
compound
erad
latent
viru
immunocompet
peopl
treatment
recurr
lesion
provid
modest
clinic
benefit
compound
use
suppress
therapi
long
term
prevent
viral
reactiv
drug
stop
reactiv
viru
resum
clearli
treatment
option
reduc
frequenc
clinic
recurr
viral
shed
badli
need
clinic
syndrom
aid
first
describ
human
immunodefici
viru
hiv
identifi
shortli
thereaft
emerg
rel
recent
deeper
understand
fundament
process
viral
replic
avail
start
initi
pharmacolog
attack
hiv
hiv
retroviru
therefor
lifecycl
requir
uniqu
revers
transcript
viral
rna
dna
action
viral
revers
transcriptas
rt
mammalian
cell
encod
revers
transcriptas
offer
attract
target
therapeut
might
expect
rel
nontox
first
success
attempt
target
hiv
rt
compound
analog
acyclovir
nucleosid
analog
first
class
drug
known
nucleosid
revers
transcriptas
inhibitor
nrti
azt
remark
efficaci
patient
advanc
aid
azt
higher
affin
viral
rt
cellular
polymeras
thu
select
inhibit
rt
function
nrti
highli
success
class
antihiv
compound
approv
fda
sever
latestag
develop
success
nrti
howev
problem
soon
becam
appar
dramat
initi
clinic
benefit
azt
often
prove
transitori
viral
resist
soon
began
appear
patient
drug
resist
seriou
problem
hiv
infect
due
high
mutat
frequenc
hiv
polymeras
coupl
high
rate
hiv
replic
make
matter
wors
mani
resist
virus
fact
show
signific
crossresist
nrti
analog
multidrug
regimen
use
treat
bacteri
infect
cancer
combin
nrti
tri
crossresist
continu
signific
problem
clearli
need
fight
hiv
drug
act
aspect
viral
life
cycl
differ
target
nucleosid
analog
made
differ
enorm
bodi
basic
knowledg
regard
replic
hiv
sever
step
viral
replic
cycl
made
attract
target
process
quit
distinct
process
necessari
life
normal
uninfect
human
cell
anoth
target
attack
viral
proteas
via
socal
proteas
inhibitor
replic
cycl
hiv
translat
code
rna
strand
lead
product
singl
polypeptid
polypeptid
must
cleav
hiv
proteas
gener
function
protein
requir
viral
replic
without
cleavag
viral
replic
ceas
first
proteas
inhibitor
drug
approv
hiv
saquinavir
introduc
impact
class
compound
immedi
dramat
sinc
proteas
inhibitor
target
complet
differ
aspect
viral
replic
cycl
nrti
crossresist
rel
infrequ
occurr
use
combin
nrti
proteas
inhibitor
mani
patient
near
death
experienc
dramat
improv
viral
load
often
fall
limit
detect
combin
therapi
regimen
come
known
highli
activ
antiretrovir
therapi
haart
introduct
haart
regimen
made
hiv
infect
chronic
condit
manag
success
year
mani
patient
current
proteas
inhibitor
avail
hiv
infect
other
develop
success
introduct
proteas
inhibitor
worker
sought
mechan
select
attack
hiv
replic
success
nrti
demonstr
viral
revers
transcriptas
excel
target
pharmacolog
attack
therefor
nonnucleosid
drug
sought
could
inhibit
rt
function
first
nonnucleosid
revers
transcriptas
inhibitor
nnrti
clinic
approv
nevirapin
nnrti
function
bind
hydrophob
pocket
subunit
hiv
rt
nnrti
becom
extrem
import
part
antihiv
armamentarium
sever
reason
like
nrti
nnrti
extrem
effect
drug
due
central
role
play
viral
rt
hiv
replic
howev
sinc
attack
hiv
rt
complet
differ
mechan
crossresist
nnrti
nrti
rare
fact
number
effect
haart
regimen
describ
combin
nrti
nnrti
without
need
proteas
inhibitor
anoth
attract
featur
nnrti
toxic
profil
quit
differ
proteas
inhibitor
despit
dramat
efficaci
proteas
inhibitorcontain
haart
regimen
longterm
use
proteas
inhibitor
associ
abnorm
lipid
glucos
metabol
chang
bodi
shape
patient
experienc
side
effect
abil
halt
proteas
inhibitor
maintain
viral
control
critic
addit
multipl
class
drug
choos
advantag
patient
treat
extend
period
eventu
develop
resist
previous
effect
drug
anoth
aspect
hiv
replic
cycl
long
eye
investig
initi
entri
viru
viral
envelop
fuse
cell
membran
first
class
compound
fusion
inhibitor
recent
approv
fda
clinic
use
compound
origin
known
name
enfuvirtid
consist
amino
acid
polypeptid
ident
portion
hiv
surfac
protein
protein
critic
fusion
process
releas
highenergi
configur
bind
receptor
enfuvirtid
interfer
process
thu
prevent
infect
new
cell
hiv
sinc
use
complet
differ
mechan
action
class
antihiv
drug
enfuvirtid
especi
use
treatmentexperienc
patient
viru
resist
class
drug
import
limit
enfuvirtid
clinic
practic
howev
fact
composit
peptid
drug
degrad
gastrointestin
tract
therefor
must
administ
inject
concept
fusion
inhibitor
class
compound
remain
attract
howev
even
oral
avail
drug
develop
final
antihiv
target
discuss
yet
come
clinic
fruition
deserv
mention
uniqu
attract
target
inher
hiv
replic
cycl
integr
hiv
dna
host
chromosom
process
depend
upon
virallyencod
integras
sever
pharmaceut
compani
integras
inhibitor
variou
stage
develop
despit
larg
number
compound
avail
treat
hiv
infect
must
stress
drug
cure
hiv
therapi
must
continu
life
note
hsv
press
need
new
therapi
erad
viru
least
provid
longterm
control
minimum
drug
exposur
inconveni
worldwid
health
impact
hepat
c
viru
hcv
underestim
although
estim
vari
global
preval
thought
million
case
make
hepat
c
one
import
chronic
viral
infect
affect
human
approxim
million
american
infect
hcv
million
chronic
infect
accord
center
diseas
control
prevent
approxim
new
case
hcv
infect
year
unit
state
death
although
annual
incid
new
infect
unit
state
appear
declin
death
rate
expect
tripl
next
decad
underscor
import
epidem
vaccin
present
avail
prevent
hcv
infect
first
fdaapprov
treatment
hcv
infect
like
act
combin
proinflammatori
direct
antivir
effect
best
patient
treat
longer
cours
achiev
sustain
viral
respons
remain
without
detect
viru
six
month
complet
therapi
subsequ
combin
ribavirin
synthet
nucleosid
antivir
activ
unknown
mechan
regimen
increas
rate
sustain
viral
respons
recent
advanc
develop
pegyl
form
form
interferona
coval
conjug
monomethoxi
polyethylen
glycol
peg
form
greatli
increas
halflif
compar
standard
prepar
allow
lessfrequ
inject
avoid
period
subtherapeut
blood
level
larg
studi
recent
complet
evalu
month
combin
therapi
pegyl
ribavirin
sustain
viral
respons
rate
studi
approach
drug
develop
target
distinct
mechan
viral
replic
cycl
farthest
along
inhibitor
proteas
hcv
translat
code
rna
strand
hcv
lead
product
singl
polypeptid
must
cleav
hcv
proteas
gener
function
protein
requir
viral
replic
small
proofofconcept
studi
prototyp
proteas
inhibitor
boehring
ingelheim
given
twice
daili
two
day
hcvposit
volunt
viral
load
fell
two
three
log
patient
within
hour
treatment
viral
load
patient
fall
limit
detect
despit
fact
patient
subsequ
rebound
result
highli
encourag
potenti
futur
combin
therapi
perhap
excit
aspect
develop
new
therapi
hcv
infect
prospect
true
cure
contrast
infect
virus
hiv
hsv
current
understand
viral
host
biolog
suggest
cur
treatment
unlik
forese
futur
note
hcv
though
infect
individu
cure
even
current
avail
therapi
pegyl
interferon
plu
ribavirin
reason
predict
proteas
inhibitor
target
therapi
enter
clinic
practic
true
cure
expect
everhigh
percentag
patient
human
papillomavirus
hpv
group
nonenvelop
doublestrand
dna
virus
infect
epitheli
cell
skin
mucosa
type
hpv
known
like
mani
remain
discov
individu
type
hpv
favor
particular
anatom
site
tend
caus
characterist
manifest
exampl
subset
hpv
type
preferenti
infect
anogenit
mucosa
type
especi
type
strongli
associ
cervic
dysplasia
carcinoma
vaccin
hpv
type
recent
shown
good
efficaci
prevent
infect
use
vaccin
may
eventu
decreas
incid
cervic
cancer
howev
hpv
type
strongli
associ
anogenit
wart
condyloma
treatment
wart
especi
anogenit
wart
problemat
standard
therapi
abl
reli
upon
destroy
infect
tissu
caustic
agent
cryotherapi
laser
treatment
etc
hope
minim
damag
surround
normal
tissu
gener
respons
rate
unsatisfactori
clinic
success
achiev
complic
frequenc
recurr
hand
spontan
remiss
wart
also
common
suggest
immunolog
respons
hpv
may
critic
control
thu
attent
focus
upon
possibl
immun
modul
treatment
option
hpv
variou
approach
attempt
two
compound
imiquimod
achiev
signific
success
although
interferon
therapi
anogenit
wart
administ
topic
system
effort
focus
intralesion
therapi
topic
treatment
disappoint
efficaci
system
therapi
associ
signific
side
effect
intralesion
therapi
perform
use
either
purifi
recombin
control
trial
intralesion
therapi
interferon
two
three
time
per
week
week
associ
complet
wart
remiss
rate
rang
recurr
rate
averag
even
intralesion
therapi
system
flulik
symptom
common
side
effect
addit
process
inject
individu
lesion
timeconsum
pain
despit
drawback
efficaci
interferon
therapi
support
concept
immun
modul
treatment
modal
anogenit
wart
success
attempt
regard
immun
respons
modifi
imiquimod
imiquimod
imidazoquinolin
deriv
stimul
multipl
aspect
innat
adapt
immun
system
specif
imiquimod
induc
multipl
cytokin
socal
thelper
type
respons
includ
tumor
necrosi
similar
respons
seen
spontan
regress
wart
although
molecular
mechan
effect
initi
unknown
later
demonstr
imiquimod
stimul
respons
via
tolllik
receptor
tlr
famili
receptor
recogn
pathogenassoci
molecular
pattern
pamp
form
basi
detect
danger
innat
immun
system
tlr
highli
express
dendrit
cell
profession
antigen
present
cell
ligat
receptor
strongli
promot
matur
cytokin
product
cell
immun
system
signal
via
administr
imiquimod
specif
result
gener
vigor
respons
clinic
imiquimod
approv
fda
treatment
anogenit
wart
administ
cream
appli
topic
approxim
three
time
per
week
cream
selfappli
applic
pain
presum
increas
patient
complianc
rate
complet
elimin
wart
week
therapi
rang
depend
exact
popul
studi
gener
women
respond
better
imiquimod
men
differ
suggest
relat
lower
degre
keratin
affect
site
femal
time
complet
remiss
wart
rang
week
women
respond
faster
men
imiquimod
also
appear
use
reduc
rate
recurr
surgic
excis
anogenit
wart
success
imiquimod
like
presag
develop
immun
respons
modul
differ
spectra
action
differ
diseas
target
one
potenti
import
agent
resiquimod
structual
relat
imiquimod
resiquimod
also
act
via
effect
tlr
specif
resiquimod
shown
activ
suppress
recurr
herp
simplex
viru
infect
one
studi
mean
time
recurr
lesion
day
resiquimodtr
patient
compar
day
vehicletr
patient
indic
immun
respons
modul
may
also
extend
beyond
infecti
diseas
imiquimod
shown
signific
activ
basal
cell
carcinoma
develop
new
therapi
viral
infect
remain
activ
field
like
remain
indefinit
certainli
much
still
done
treatment
hsv
hiv
hcv
hpv
consid
adequ
furthermor
emerg
virus
west
nile
viru
sar
coronaviru
ebola
suggest
new
challeng
continu
aris
fortun
everincreas
understand
viral
replic
togeth
advanc
cell
biolog
immunolog
provid
us
good
basi
develop
new
effect
therapi
meet
threat
